• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the International Osteoporosis Foundation.

作者信息

Delmas Pierre D, Rizzoli René, Cooper Cyrus, Reginster Jean-Yves

出版信息

Osteoporos Int. 2005 Jan;16(1):1-5. doi: 10.1007/s00198-004-1813-0.

DOI:10.1007/s00198-004-1813-0
PMID:15565349
Abstract
摘要

相似文献

1
Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the International Osteoporosis Foundation.对绝经后骨质疏松症患者进行治疗是值得的。国际骨质疏松基金会的立场。
Osteoporos Int. 2005 Jan;16(1):1-5. doi: 10.1007/s00198-004-1813-0.
2
Different effects of antiresorptive therapies on vertebral and nonvertebral fractures in postmenopausal osteoporosis.抗吸收疗法对绝经后骨质疏松症患者椎体和非椎体骨折的不同影响。
Bone. 2002 Jan;30(1):14-7. doi: 10.1016/s8756-3282(01)00667-6.
3
Bisphosphonates in the treatment of osteoporosis. Principles and efficacy.双膦酸盐类药物治疗骨质疏松症。原理与疗效。
Ann Med Interne (Paris). 2000 Oct;151(6):504-10.
4
Alendronate in postmenopausal osteoporosis.阿仑膦酸盐用于绝经后骨质疏松症
N Engl J Med. 1996 Mar 14;334(11):733-4; author reply 734-5.
5
[Osteoporosis therapy compared. More solid bones with bisphosphonates].[骨质疏松症治疗对比。双膦酸盐使骨骼更强健]
MMW Fortschr Med. 2003 Aug 7;145(31-32):55.
6
Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.口服阿仑膦酸钠对绝经后骨质疏松症骨密度及骨折发生率的影响。阿仑膦酸钠Ⅲ期骨质疏松症治疗研究组。
N Engl J Med. 1995 Nov 30;333(22):1437-43. doi: 10.1056/NEJM199511303332201.
7
[Osteoporotic fracture in menopausal women: alendronate reduces the risk].绝经后女性骨质疏松性骨折：阿仑膦酸盐可降低风险
Rev Med Suisse. 2008 Dec 10;4(183):2703.
8
Low frequency of treatment of osteoporosis among postmenopausal women following a fracture.绝经后女性骨折后骨质疏松症治疗率低。
Arch Intern Med. 2003 Sep 22;163(17):2052-7. doi: 10.1001/archinte.163.17.2052.
9
[Fewer fractures after just 6 months. Fast help for tired bones].
MMW Fortschr Med. 2002 Nov 28;144(48):61.
10
[To treat effectively without delay. The data on fractures decisive].及时有效治疗。骨折数据起决定性作用。
MMW Fortschr Med. 2003 May 22;145(21):56-7.

引用本文的文献

1
Sequential therapy following teriparatide treatment in patients at high risk of osteoporotic patients.在骨质疏松症高危患者中，特立帕肽治疗后的序贯治疗。
J Bone Miner Metab. 2025 Jan;43(1):22-25. doi: 10.1007/s00774-025-01584-0. Epub 2025 Mar 22.
2
Effects of kinect-based virtual reality training on bone mineral density and fracture risk in postmenopausal women with osteopenia: a randomized controlled trial.基于 Kinect 的虚拟现实训练对绝经后骨质疏松症妇女骨密度和骨折风险的影响：一项随机对照试验。
Sci Rep. 2024 Mar 20;14(1):6650. doi: 10.1038/s41598-024-57358-7.
3
Predictors of mortality one year after pelvic fractures in an older population: a retrospective cohort study.

本文引用的文献

1
Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study.雷洛昔芬在英国的成本效益：基于MORE研究的经济学评估。
Osteoporos Int. 2005 Jan;16(1):15-25. doi: 10.1007/s00198-004-1688-0. Epub 2004 Jul 24.
2
Official positions of the international society for clinical densitometry.国际临床骨密度测量学会的官方立场。
J Clin Endocrinol Metab. 2004 Aug;89(8):3651-5. doi: 10.1210/jc.2004-0124.
3
Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis.
老年人群骨盆骨折 1 年后死亡率的预测因素：一项回顾性队列研究。
Arch Osteoporos. 2024 Mar 14;19(1):16. doi: 10.1007/s11657-024-01373-8.
4
Fragility Fractures in Postmenopausal Women: Development of 5-Year Prediction Models Using the FRISBEE Study.绝经后妇女的脆性骨折：使用 FRISBEE 研究开发的 5 年预测模型。
J Clin Endocrinol Metab. 2022 May 17;107(6):e2438-e2448. doi: 10.1210/clinem/dgac092.
5
Individualized fracture risk assessment: State-of-the-art and room for improvement.个性化骨折风险评估：现状与改进空间。
Osteoporos Sarcopenia. 2018 Mar;4(1):2-10. doi: 10.1016/j.afos.2018.03.001. Epub 2018 Mar 22.
6
Disease burden of fractures among patients with osteoporosis in Japan: health-related quality of life, work productivity and activity impairment, healthcare resource utilization, and economic costs.日本骨质疏松症患者骨折的疾病负担：与健康相关的生活质量、工作生产力和活动障碍、医疗资源利用和经济成本。
J Bone Miner Metab. 2019 Mar;37(2):307-318. doi: 10.1007/s00774-018-0916-1. Epub 2018 Mar 8.
7
Genetic profiling and individualized assessment of fracture risk.基因谱分析和骨折风险的个体化评估。
Nat Rev Endocrinol. 2013 Mar;9(3):153-61. doi: 10.1038/nrendo.2013.3. Epub 2013 Feb 5.
8
Bone density, balance and quality of life of postmenopausal women taking alendronate participating in different physical activity programs.服用阿仑膦酸钠的绝经后妇女的骨密度、平衡和生活质量与参与不同体育活动方案的关系。
Ther Adv Musculoskelet Dis. 2010 Aug;2(4):175-85. doi: 10.1177/1759720X10374677.
9
Genetics and the individualized prediction of fracture.遗传学与骨折的个体化预测。
Curr Osteoporos Rep. 2012 Sep;10(3):236-44. doi: 10.1007/s11914-012-0113-4.
10
Prevalent vertebral fractures predict subsequent radiographic vertebral fractures in postmenopausal Korean women receiving antiresorptive agent.在接受抗吸收剂治疗的绝经后韩国女性中，普遍存在的椎体骨折可预测随后的放射性椎体骨折。
Osteoporos Int. 2011 Mar;22(3):781-7. doi: 10.1007/s00198-010-1298-y. Epub 2010 Jun 9.
静脉注射伊班膦酸盐剂量不足与绝经后骨质疏松症抗骨折疗效欠佳有关。
Bone. 2004 May;34(5):890-9. doi: 10.1016/j.bone.2004.01.008.
4
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.雷奈酸锶对绝经后骨质疏松症女性椎体骨折风险的影响。
N Engl J Med. 2004 Jan 29;350(5):459-68. doi: 10.1056/NEJMoa022436.
5
Screening for osteoporosis in postmenopausal women: recommendations and rationale.绝经后女性骨质疏松症筛查：建议及依据。
Ann Intern Med. 2002 Sep 17;137(6):526-8. doi: 10.7326/0003-4819-137-6-200209170-00014.
6
Treatment of postmenopausal osteoporosis.绝经后骨质疏松症的治疗。
Lancet. 2002 Jun 8;359(9322):2018-26. doi: 10.1016/S0140-6736(02)08827-X.
7
Diagnosis of osteoporosis and assessment of fracture risk.骨质疏松症的诊断与骨折风险评估。
Lancet. 2002 Jun 1;359(9321):1929-36. doi: 10.1016/S0140-6736(02)08761-5.
8
The use of placebo-controlled and non-inferiority trials for the evaluation of new drugs in the treatment of postmenopausal osteoporosis.使用安慰剂对照试验和非劣效性试验来评估新药治疗绝经后骨质疏松症的效果。
Osteoporos Int. 2002 Jan;13(1):1-5. doi: 10.1007/s198-002-8331-3.
9
Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds.根据骨密度和诊断阈值得出的骨质疏松性骨折的十年概率。
Osteoporos Int. 2001 Dec;12(12):989-95. doi: 10.1007/s001980170006.
10
Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies.骨质疏松性骨折的十年风险及风险因素对筛查策略的影响。
Bone. 2002 Jan;30(1):251-8. doi: 10.1016/s8756-3282(01)00653-6.